Journal of Internal Medicine Concepts & Practice ›› 2023, Vol. 18 ›› Issue (04): 234-238.doi: 10.16138/j.1673-6087.2023.04.004
• Expert forum • Previous Articles Next Articles
WU Luming, WANG Weiqing(
)
Received:2023-06-15
Online:2023-08-30
Published:2024-01-09
CLC Number:
WU Luming, WANG Weiqing. Clinical and basic research on adrenal cortical carcinoma[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 234-238.
| [1] |
Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors[J]. Eur J Endocrinol, 2023, 189(1): G1-G42.
doi: 10.1093/ejendo/lvad066 pmid: 37318239 |
| [2] |
Rodriguez-Galindo C, Krailo MD, Pinto EM, et al. Treatment of pediatric adrenocortical carcinoma with surgery, retroperitoneal lymph node dissection, and chemotherapy: the Children’s Oncology Group ARAR0332 protocol[J]. J Clin Oncol, 2021, 39(22): 2463-2473.
doi: 10.1200/JCO.20.02871 URL |
| [3] |
Crona J, Beuschlein F. Adrenocortical carcinoma-towards genomics guided clinical care[J]. Nat Rev Endocrinol, 2019, 15(9): 548-560.
doi: 10.1038/s41574-019-0221-7 |
| [4] |
Raj N, Zheng Y, Kelly V, et al. PD-1 blockade in advanced adrenocortical carcinoma[J]. J Clin Oncol, 2020, 38(1): 71-80.
doi: 10.1200/JCO.19.01586 pmid: 31644329 |
| [5] |
Assié G, Jouinot A, Fassnacht M, et al. Value of molecular classification for prognostic assessment of adrenocortical carcinoma[J]. JAMA Oncol, 2019, 5(10): 1440-1447.
doi: 10.1001/jamaoncol.2019.1558 URL |
| [6] |
Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(11): 1476-1490.
doi: 10.1016/j.annonc.2020.08.2099 pmid: 32861807 |
| [7] |
Cavlan D, Bharwani N, Grossman A. Androgen- and estrogen-secreting adrenal cancers[J]. Semin Oncol, 2010, 37(6): 638-648.
doi: 10.1053/j.seminoncol.2010.10.016 pmid: 21167382 |
| [8] |
Staubitz WJ, Oberkircher OJ, Lent MH, et al. Feminization in an adult male with adrenal cortical carcinoma[J]. N Y State J Med, 1954, 54(18): 2565-2572.
pmid: 13194130 |
| [9] |
Moreno S, Guillermo M, Decoulx M, et al. Feminizing adreno-cortical carcinomas in male adults[J]. Ann Endocrinol (Paris), 2006, 67(1): 32-38.
doi: 10.1016/S0003-4266(06)72537-9 URL |
| [10] |
Gabrilove JL, Sharma DC, Wotiz HH, et al. Feminizing adrenocortical tumors in the male[J]. Medicine (Baltimore), 1965, 44: 37-79.
doi: 10.1097/00005792-196501000-00002 URL |
| [11] |
Barnard L, Schiffer L, Louw du-Toit R, et al. 11-oxygenated estrogens are a novel class of human estrogens but do not contribute to the circulating estrogen pool[J]. Endocrinology, 2021, 162(3): bqaa231.
doi: 10.1210/endocr/bqaa231 URL |
| [12] |
Yokoyama M, Kijima T, Takada-Owada A, et al. A case of estrogen-secreting adrenocortical carcinoma[J]. IJU Case Rep, 2021, 4(5): 318-321.
doi: 10.1002/iju5.v4.5 URL |
| [13] |
Mamoojee Y, Ganguri M, Taylor N, et al. Clinical case seminar: postmenopausal androgen excess-challenges in diagnostic work-up and management of ovarian thecosis[J]. Clin Endocrinol (Oxf), 2018, 88(1): 13-20.
doi: 10.1111/cen.2018.88.issue-1 URL |
| [14] |
Goto T, Murakami O, Sato F, et al. Oestrogen producing adrenocortical adenoma: clinical, biochemical and immunohistochemical studies[J]. Clin Endocrinol(Oxf), 1996, 45(5): 643-648.
doi: 10.1046/j.1365-2265.1996.00833.x URL |
| [15] |
Tezuka Y, Yamazaki Y, Ono Y, et al. Unique sex steroid profiles in estrogen-producing adrenocortical adenoma associated with bilateral hyperaldosteronism[J]. J Endocr Soc, 2020, 4(2): bvaa004.
doi: 10.1210/jendso/bvaa004 URL |
| [16] | Mermejo LM, Carvalho FG, Molina CAF, et al. Estrogen-secreting adrenocortical tumor in a postmenopausal woman[J]. Endocrinol Diabetes Metab Case Rep, 2021, 2021: 20-0214. |
| [17] |
Wu L, Xie J, Jiang L, et al. Feminizing adrenocortical carcinoma: the source of estrogen production and the role of adrenal-gonadal dedifferentiation[J]. J Clin Endocrinol Metab, 2018, 103(10): 3706-3713.
doi: 10.1210/jc.2018-00689 pmid: 30053001 |
| [18] |
Fujisawa Y, Sakaguchi K, Ono H, et al. Combined steroidogenic characters of fetal adrenal and Leydig cells in childhood adrenocortical carcinoma[J]. J Steroid Biochem Mol Biol, 2016, 159: 86-93.
doi: 10.1016/j.jsbmb.2016.02.031 URL |
| [19] |
Schröder MAM, Sweep FCGJ, van Herwaarden AE, et al. Transcriptional comparison of testicular adrenal rest tumors with fetal and adult tissues[J]. Eur J Endocrinol, 2022, 187(5): 607-615.
doi: 10.1530/EJE-22-0143 pmid: 36047744 |
| [20] |
Greenhill C. Adrenal gland: the genetics of adrenocortical carcinoma revealed[J]. Nat Rev Endocrinol, 2016, 12(8): 433.
doi: 10.1038/nrendo.2016.89 pmid: 27259178 |
| [21] |
Zheng S, Cherniack AD, Dewal N, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma[J]. Cancer Cell, 2016, 29(5): 723-736.
doi: S1535-6108(16)30160-X pmid: 27165744 |
| [22] |
Wu L, Xie J, Qi Y, et al. Mutational landscape of non-functional adrenocortical adenomas[J]. Endocr Relat Cancer, 2022, 29(9): 521-532.
doi: 10.1530/ERC-21-0410 URL |
| [23] |
Lerario AM, Mohan DR, Hammer GD. Update on biology and genomics of adrenocortical carcinomas: rationale for emerging therapies[J]. Endocr Rev, 2022, 43(6): 1051-1073.
doi: 10.1210/endrev/bnac012 pmid: 35551369 |
| [24] |
Libé R, Borget I, Ronchi CL, et al. Prognostic factors in stage Ⅲ-Ⅳ adrenocortical carcinomas(ACC)[J]. Ann Oncol, 2015, 26: 2119-2125.
doi: 10.1093/annonc/mdv329 pmid: 26392430 |
| [25] | Roca E, Berruti A, Sbiera S, et al. Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer[J]. Endocr Relat Cancer, 2017, 24(7): 319-327. |
| [26] |
Wilmouth JJ Jr, Olabe J, Garcia-Garcia D, et al. Sexually dimorphic activation of innate antitumor immunity prevents adrenocortical carcinoma development[J]. Sci Adv, 2022, 8(41): eadd0422.
doi: 10.1126/sciadv.add0422 URL |
| [27] |
Pearlstein SS, Conroy PC, Menut KC, et al. Evaluation of necrosis as a diagnostic and prognostic indicator in adrenocortical carcinoma[J]. JAMA Surg, 2021, 156(12): 1173-1174.
doi: 10.1001/jamasurg.2021.3646 pmid: 34495300 |
| [28] |
Nazha B, Zhuang TZ, Dada HI, et al. Blood-based next-generation sequencing in adrenocortical carcinoma[J]. Oncologist, 2022, 27(6): 462-468.
doi: 10.1093/oncolo/oyac061 pmid: 35462410 |
| [29] |
Relav L, Doghman-Bouguerra M, Ruggiero C, et al. Steroidogenic factor 1, a goldilocks transcription factor from adrenocortical organogenesis to malignancy[J]. Int J Mol Sci, 2023, 24(4): 3585.
doi: 10.3390/ijms24043585 URL |
| [30] |
Catalano R, Giardino E, Treppiedi D, et al. The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells[J]. Cancer Lett, 2021, 497: 77-88.
doi: 10.1016/j.canlet.2020.10.022 pmid: 33075426 |
| [31] |
Elhassan YS, Altieri B, Berhane S, et al. S-GRAS score for prognostic classification of adrenocortical carcinoma[J]. Eur J Endocrinol, 2021, 186(1): 25-36.
doi: 10.1530/EJE-21-0510 pmid: 34709200 |
| [32] |
Mohan DR, Lerario AM, Else T, et al. Targeted assessment of G0S2 methylation identifies a rapidly recurrent, routinely fatal molecular subtype of adrenocortical carcinoma[J]. Clin Cancer Res, 2019, 25(11): 3276-3288.
doi: 10.1158/1078-0432.CCR-18-2693 URL |
| [33] |
Gara SK, Lack J, Zhang L, et al. Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors[J]. Nat Commun, 2018, 9(1): 4172.
doi: 10.1038/s41467-018-06366-z pmid: 30301885 |
| [34] |
Kerdivel G, Amrouche F, Calmejane MA, et al. DNA hypermethylation driven by DNMT1 and DNMT3A favors tumor immune escape contributing to the aggressiveness of adrenocortical carcinoma[J]. Clin Epigenetics, 2023, 15(1): 121.
doi: 10.1186/s13148-023-01534-5 pmid: 37528470 |
| [1] | ZHOU Weiwei, WANG Weiqing. Evolution of understanding of primary bilateral macronodular adrenal hyperplasia [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 239-241. |
| [2] | ZHANG Cui, WANG Weiqing. Ectopic adrenocorticotropic hormone syndrome [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 242-246. |
| [3] | ZHOU Weiwei, ZHENG Sichang, WANG Weiqing. New understanding of mechanism of Cushing’s disease [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 247-250. |
| [4] | JIANG Yiran, WANG Weiqing. Research progress on molecular mechanism of primary aldosteronism [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 261-265. |
| [5] | KE Yuya, GONG Yanchun. Research progress of cardiovascular damage in primary aldosteronism [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 301-304. |
| [6] | GU Yanyun, ZHOU Weiwei, WANG Weiqing, et al. Primary pigmented nodular adrenocortical disease [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 230-233. |
| [7] | LAI Liqin, GONG Yanchun. Research progress of chronic kidney injury in primary aldosteronism [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(03): 211-214. |
| [8] | Chinese Society of Endocrinology. Guidelines for clinical management of adrenal disease novel coronavirus infection [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(01): 16-17. |
| [9] | . [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(03): 205-207. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
